Cargando…
CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy
BACKGROUND: During the first years of the use of direct acting Hepatitis C antiviral drugs (DAAS), several studies reported a possible correlation between this new era of treatment and an increased risk of Hepatocellular carcinoma (HCC). Its development could possibly be favored by the changes in th...
Autores principales: | El Menshawy, Nadia, Hassan, Noha, Khariza, Mohamed, AlAshery, Hala, Baghat, Monir, Ashour, Rehab |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Makerere Medical School
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398471/ https://www.ncbi.nlm.nih.gov/pubmed/37545943 http://dx.doi.org/10.4314/ahs.v23i1.22 |
Ejemplares similares
-
Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016) -
Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
por: Hassuna, Noha Anwar, et al.
Publicado: (2022) -
Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir
por: Ashraf, Taha, et al.
Publicado: (2017) -
Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection
por: Ahmed, Ossama A, et al.
Publicado: (2018) -
Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure
por: Mohamed, Hala, et al.
Publicado: (2022)